T. Rowe Price Associates’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.1B | Buy |
2,069,677
+1,780,170
| +615% | +$822M | 0.11% | 153 |
|
|
2026
Q1 | $139M | Buy |
289,507
+172,926
| +148% | +$88.5M | 0.02% | 545 |
|
|
2025
Q4 | $65.5M | Buy |
116,581
+14,253
| +14% | +$8.09M | 0.01% | 726 |
|
|
2025
Q3 | $52.6M | Sell |
102,328
-976
| -0.9% | -$426K | 0.01% | 796 |
|
|
2025
Q2 | $32.4M | Sell |
103,304
-4,071
| -4% | -$1.22M | ﹤0.01% | 846 |
|
|
2025
Q1 | $32.7M | Sell |
107,375
-18,343
| -15% | -$6.17M | ﹤0.01% | 834 |
|
|
2024
Q4 | $41.8M | Sell |
125,718
-5,814
| -4% | -$1.97M | ﹤0.01% | 810 |
|
|
2024
Q3 | $43.9M | Sell |
131,532
-22,755
| -15% | -$8.64M | 0.01% | 793 |
|
|
2024
Q2 | $63.5M | Sell |
154,287
-101,813
| -40% | -$40.3M | 0.01% | 645 |
|
|
2024
Q1 | $104M | Buy |
256,100
+3,222
| +1% | +$1.13M | 0.01% | 542 |
|
|
2023
Q4 | $77.5M | Sell |
252,878
-13,619
| -5% | -$3.68M | 0.01% | 594 |
|
|
2023
Q3 | $64.5M | Sell |
266,497
-58,619
| -18% | -$15M | 0.01% | 604 |
|
|
2023
Q2 | $78.1M | Sell |
325,116
-1,895
| -0.6% | -$394K | 0.01% | 582 |
|
|
2023
Q1 | $61.5M | Sell |
327,011
-14,710
| -4% | -$3.04M | 0.01% | 623 |
|
|
2022
Q4 | $72.6M | Sell |
341,721
-17,146
| -5% | -$3.43M | 0.01% | 563 |
|
|
2022
Q3 | $56.4M | Sell |
358,867
-30,722
| -8% | -$4.9M | 0.01% | 615 |
|
|
2022
Q2 | $58.3M | Sell |
389,589
-88,337
| -18% | -$12.8M | 0.01% | 829 |
|
|
2022
Q1 | $78.2M | Sell |
477,926
-15,330
| -3% | -$2.53M | 0.01% | 810 |
|
|
2021
Q4 | $107M | Sell |
493,256
-19,973
| -4% | -$4.18M | 0.01% | 742 |
|
|
2021
Q3 | $97.1M | Sell |
513,229
-189,782
| -27% | -$34.6M | 0.01% | 778 |
|
|
2021
Q2 | $124M | Sell |
703,011
-53,841
| -7% | -$9.29M | 0.01% | 708 |
|
|
2021
Q1 | $124M | Sell |
756,852
-24,021
| -3% | -$3.67M | 0.01% | 704 |
|
|
2020
Q4 | $109M | Sell |
780,873
-6,425
| -0.8% | -$810K | 0.01% | 700 |
|
|
2020
Q3 | $88M | Buy |
787,298
+3,525
| +0.4% | +$408K | 0.01% | 693 |
|
|
2020
Q2 | $72.9M | Buy |
783,773
+1,936
| +0.2% | +$165K | 0.01% | 725 |
|
|
2020
Q1 | $57.4M | Buy |
781,837
+20,444
| +3% | +$1.77M | 0.01% | 737 |
|
|
2019
Q4 | $64M | Buy |
761,393
+19,802
| +3% | +$1.53M | 0.01% | 818 |
|
|
2019
Q3 | $62.3M | Buy |
741,591
+162,612
| +28% | +$12.3M | 0.01% | 785 |
|
|
2019
Q2 | $37.9M | Buy |
578,979
+283,143
| +96% | +$16.3M | 0.01% | 981 |
|
|
2019
Q1 | $17.4M | Buy |
295,836
+290,672
| +5,629% | +$17.4M | ﹤0.01% | 1215 |
|
|
2018
Q4 | $273K | Buy |
5,164
+318
| +7% | +$17.5K | ﹤0.01% | 2326 |
|
|
2018
Q3 | $290K | Buy |
+4,846
| New | +$265K | ﹤0.01% | 2368 |
|
Other funds holding MEDP
WA
T. Rowe Price Associates's MEDP Position: Q2 2026 in Review
T. Rowe Price Associates increased its Medpace (MEDP) stake by 615% in Q2 2026, buying an estimated $822M and bringing the position to 2,069,677 shares worth $1.1B. The position accounts for 0.11% of the portfolio, ranked #153.
T. Rowe Price Associates first reported a position in MEDP in Q3 2018 and has held it in 32 quarters since. 694 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.
- T. Rowe Price Associates held 2,069,677 shares of Medpace worth $1.1B as of Q2 2026.
- T. Rowe Price Associates bought 1,780,170 Medpace shares in Q2 2026, an estimated $822M.
- Medpace made up 0.11% of T. Rowe Price Associates's portfolio in Q2 2026, its #153 holding.
- T. Rowe Price Associates first reported a position in Medpace in Q3 2018 and has held it in 32 quarters since.
- 694 funds tracked by Wall St. Rank held Medpace as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.